Circular RNA MYLK promotes hepatocellular carcinoma progression by increasing Rab23 expression by sponging miR-362-3p

Zhiqin Li*†, Yushu Hu†, Qinglei Zeng†, Hongyan Wang, Jingya Yan, Hua Li and Zujiang Yu*

Abstract

Background: CircRNA myosin light chain kinase (circRNA MYLK) has been shown to promote the progression of various tumor diseases. The purpose of this study was to explore the potential molecular mechanism of circMYLK in hepatocellular carcinoma (HCC).

Methods: The quantitative Real-Time PCR (qRT-PCR) was used to measure the expressions of circMYLK, miR-362-3p and Rab23 in HCC tissues and cell lines. Huh7 and Hep3B cells were selected to explore the role of circMYLK in proliferation, invasion and migration of HCC cells in vitro. The interaction among circMYLK, miR-362-3p and Rab23 was investigated by biological information and dual luciferase gene reporter assay. The effect of circMYLK on HCC tumor growth in vivo was studied in a tumor xenograft model in mice.

Results: CircMYLK was highly expressed in HCC tissues and cell lines, which was associated with poor prognosis in HCC patients. In addition, knockdown of circMYLK remarkably inhibited the proliferation, invasion, and migration of Huh7 and Hep3B cells. MiR-362-3p was a direct target of circMYLK, and Rab23 was a direct target gene of miR-362-3p. Meanwhile, circMYLK was negatively correlated with the expression of miR-362-3p and positively correlated with Rab23 expression. Moreover, either overexpressed miR-362-3p or silencing Rab23 could observably suppress the enhanced proliferation, invasion, and migration induced by circMYLK in Huh7 and Hep3B cells. Finally, knockdown of circMYLK and overexpressed miR-362-3p could suppress the expression of Rab23, thus inhibiting the growth and proliferation of Hep3B cells in vivo.

Conclusion: circMYLK promotes the occurrence and development of HCC by regulating the miR-362-3p/Rab23 axis, which provides a novel direction and theoretical basis for the early diagnosis and treatment of HCC.

Keywords: Hepatocellular carcinoma, circRNAs MYLK, miR-362-3p, Rab23

Background

Hepatocellular carcinoma (HCC) is the most common primary tumour in the liver, its main pathogenic factors are hepatitis and cirrhosis caused by drinking, fatty liver, and hepatitis virus [1, 2]. HCC is characterized by high incidence, late detection and poor prognosis [3, 4]. Currently, HCC is mainly treated by surgical resection and liver transplantation, but only in the early stage of tumour [5]. The study believes that the occurrence and development of HCC is a result of the synergistic effect of multiple factors and stages, and is related to the involvement of multiple oncogenes and related tumor suppressor, even the non-coding RNA [6, 7]. Therefore, it is extremely necessary to find effective therapeutic targets for HCC.

CIRCUrna (cirRNA) is a kind of special non-coding RNA, which formed a loop stable structure to avoid the degradation of RNase enzyme [8, 9]. At present, cirRNAs can play a crucial role in regulating gene expressions by acting as microRNA (miRNA) sponges, RNA-binding protein (RBP) sequestering agents, and...
transcription regulators [10]. Multiple circRNAs have been found to be associated with liver cancer and play an important role in HCC [11, 12]. CircRNA MYLK is an important molecule that regulates myosin function and affects cytoskeleton, cell proliferation, and muscle contraction [13]. CircRNA MYLK was shown to promote the progression of various tumor diseases [14, 15]. However, current studies on the role of circRNA MYLK in HCC are relatively scarce.

It was well-known that circRNA can bind to miRNA to influence the biological behavior of tumors [16]. Meanwhile, miRNA is an evolutionarily conserved non-coding small RNA that binds to the 3′ UTR region of the target gene, leading to degradation of mRNA or inhibition of mRNA translation, thereby regulating gene transcription [17, 18]. Studies have shown that multiple miRNAs are abnormally expressed in liver cancer specimens and participates in the progression of HCC by regulating cell proliferation, survival and invasion [19, 20]. Thus, it is speculated that certain miRNAs may be potential new targets for the treatment of HCC. MiR-362-3p has been shown to be abnormally expressed in a variety of tumors [21, 22]. For instance, it was reported that miR-362-3p, as a tumor suppressor, inhibited the progression of Glioma by targeting PAX3 and LUAD tumorigenesis by decreasing the E2F1, respectively [23, 24]. RAB23 is an important member of RAS proto-oncogene family and is considered as an tumor promoter [25]. Rab23 is found to be involved in the occurrence and development of liver cancer, lung cancer, breast cancer, gastric cancer, skin squamous cell cancer and thyroid cancer, and is closely related to tumor progression [26–29]. To date, the role of circMYLK in HCC has not been clarified and the underlying mechanism remains unclear. The purpose of this study was to explore the role and mechanism of circMYLK, miR-362-3p, and Rab23 in the progression of HCC, and hope to provide a new direction and theoretical basis for the early diagnosis and treatment of liver cancer.

**Materials and methods**

**Tissues collection**

HCC patients (n = 62) diagnosed by histopathology in the First Affiliated Hospital of Zhengzhou University from 2013 to 2014 were selected, and HCC tissues and adjacent non-tumor tissues were obtained by surgery. All the tissue samples were frozen with liquid nitrogen and saved in the −80 °C cryogenic refrigerator. All patients received no other treatment before surgery and were given informed consent. This study was approved by the ethics committee of the First Affiliated Hospital of Zhengzhou University (Approval Number: 2017-16125).

**Cells**

Normal liver cell lines (LO2) and human liver cancer cell lines (Hep3B, Huh7, HCCLM3, SK-Hep1, PLC, and HepG2) were obtained from the cell center of Shanghai institute of life sciences. F12K medium (10% FBS) was used to culture Hep3B cells, and RPMI 1640 medium (10% FBS) was used to culture other cells. MiR-362-3p mimic, si-Rab23, si-circMYLK and the corresponding controls were purchased from Gene Pharma (Shanghai, China). Lipofectamine 2000 (Invitrogen, Waltham, MA, USA) was used to transfect the above oligonucleotides and plasmids into cells.

**qRT-PCR assay**

The qRT-PCR experiments were performed according to the literature [30]. GAPDH was used as the internal reference of circRNA/mRNA, and U6 was used as the internal reference of miRNA. Primer sequences were shown in Table 1.

**Cell proliferation assay**

Cell proliferation was determined by cell counting kit-8 (CCK-8, Dojindo, Japan), and the specific operation steps were strictly in accordance with the instruction. In short, the transfected cells (2000 cells) were inoculated to 96-well plates for different times and incubated for 1 h in dark with CCK-8 solution of 10 μL per well. After culture, the absorbance at 450 nm was measured to reflect the proliferation activity of the cells. Meanwhile, colony formation assay was used to determine the ability of cell clone formation. In brief, the transfected cells (4000

| Table 1 | The sequences of specific primers |
|----------|----------------------------------|
| **Gene name** | **Primer sequence (5′ to3′)** |
| MYLK (convergent primer) | Forward: 5′-AGGTGAGGTCAGTGTCT-3′ |
| | Reverse: 5′-AATGTCGTGTACGTT-3′ |
| CircMYLK (divergent primer) | Forward: 5′-GAACCGCAGTGCTCAG-3′ |
| | Reverse: 5′-GTACCGGCAGTCAG-3′ |
| miR-362-3p | Forward: 5′-CAGGGACTGAGGGCAACT-3′ |
| | Reverse: 5′-TTGATTCGGAAGAGCCGAC-3′ |
| Rab23 | Forward: 5′-GAAAGTGCTCCGAAAGC-3′ |
| | Reverse: 5′-CJGCGAAGTACTTGC-3′ |
| GAPDH | Forward: 5′-ATCGAGGACAGGCCAACAC-3′ |
| | Reverse: 5′-CAGCGTCGTTGAAAGTG-3′ |
| U6 | Forward: 5′-AGACATTCGTCCGTTG-3′ |
| | Reverse: 5′-GGCCCGGATTATCCGAC-3′ |
cells) were inoculated into 6-well plates and cultured for 14 days. After fixing the cells with methanol, 0.1% crystal violet solution was used for staining, and the colonies were counted.

Transwell migration and invasion assay
Cells in serum-free medium were placed into the upper chamber of the 24-well transwell chambers, and medium containing 10% FBS was added into the lower chamber as chemoattractant. After incubation for 24 h at 37 °C, cells remaining on the upper chamber were removed with cotton wool, whereas cells adhering to the lower chamber were fixed in 1% paraformaldehyde, stained in a day solution with 0.5% crystal violet and counted. For the invasion assay, the upper chamber was coated with extracellular matrix (BD Biosciences, USA), a soluble basement membrane matrix. The rest of the assay was performed as the migration assay. The HCC cells of migration and invasion were counted and photographed in at least five random fields under a light microscopy (Olympus Corporation, Tokyo, Japan).

Double luciferase reporter gene assay
Luc-circMYLK-WT or luc-circMYLK-MUT was co-transfected into cells with MiR-362-3p mimic or its control. In addition, luc-Rab23-WT or luc-Rab23-MUT was co-transfected into cells with miR-362-3p mimic or its control. Dual luciferase assay system (Promega) was used to detect luciferase activity after transfection for 48 h.

Measurement of tumor growth in vivo
Hep3B cells (1 × 10⁶) were subcutaneously inoculated into 6-week old female thymus-free BALB/c nude mice to establish tumor xenotransplantation model. Tumor volume was measured every 3 days. When the tumor volume reached 100 mm³ (day 9), the negative control (n=6), miR-362-3p agonist (n=6) or si-circMYLK (n=6) were injected into the tumor. After 30 days of modeling, the mice were killed. This study was conducted in accordance with the First Affiliated Hospital of Zhengzhou University guidelines for the care and use of experimental animals and was approved by the First Affiliated Hospital of Zhengzhou University animal experiment ethics committee.

Western blot
Total proteins in tissues or cells were extracted with RIPA cell lysate and quantified. The extracted protein was separated by 10% SDS-PAGE gel and transferred to cellulose acetate membrane. The membrane was incubated with the GAPDH antibody (14485-1-AP, Proteintech) or Rab23 antibody (ab181602, Abcam) under 4 °C for the night, and then was incubated with the second antibody at room temperature for 1 h. ECL solution was used to color the protein bands.

Statistical analysis
All data were expressed as mean ± standard deviation (SD). Kaplan–Meier plot, Pearson correlation analysis and student T test were used for data analysis in this study. P<0.05 was considered statistically significant.

Results
CircMYLK expression in HCC cell lines and tissues
The expression of circMYLK in normal tissues (n=62) and HCC tissues (n=62) were measured by qRT-PCR. As shown in Fig. 1a, compared with the normal tissues, circMYLK expression in HCC tissues was obviously up-regulated (P<0.01). In addition, we also detected the expression of circMYLK in HCC cell lines. As shown in Fig. 1c, circMYLK expression in HCC cell lines was remarkably higher than that in LO2 cells (P<0.001, P<0.01), and circMYLK expression was highest in Hep3B and Huh7 cells, so these two types of cells were selected for follow-up experiments. No significant difference of MYLK mRNA expression was observed in HCC cell lines and HCC tissues (Fig. 1b, d). Besides, we also analyzed the relationship between circMYLK and the prognosis of HCC patients. The results found that the survival rate of patients with high-level circMYLK expression was markedly lower than that of patients with low-level circMYLK expression (Fig. 1e), and the overexpression of circMYLK was significantly correlated with patients’ extrahepatic metastasis, intrahepatic metastasis and tumor size (Table 2). As mentioned above, circMYLK might be involved in and facilitate the progression of HCC.

Effects of knockdown circMYLK on HCC cell proliferation and metastasis
The siRNA circMYLK (si-circMYLK) was transfected into Hep3B and Huh7 cells to investigate the role of knockdown circMYLK in HCC cell proliferation and metastasis. The results showed that si-circMYLK transfection remarkably inhibited the expression of circMYLK in these two types of cells (P<0.001), but had no significant effect on the expression of MYLK (Fig. 2a, P>0.05), indicating that si-circMYLK transfection successfully knocked down the expression of circMYLK. CCK-8 assay was used to indicate that knockdown of circMYLK observably reduced the cell activity of Hep3B and Huh7 cells (Fig. 2b, P<0.001, P<0.01, P<0.05). Meanwhile, colony formation assay results found that knockdown of circMYLK remarkably suppressed the colony formation ability of HCC cells (Fig. 2c, P<0.01). Besides, transwell assays showed that knockdown of circMYLK apparently decreased the invasion and migration of HCC cells.
Fig. 1 The mRNA level circMYLK in HCC cell lines and tissues. a, b Measurement of the circMYLK and MYLK mRNA expressions in adjacent normal tissues (n = 62) and HCC tissues (n = 62). c, d Measurement of circMYLK and MYLK mRNA expressions in LO2 cells and HCC cell lines. e Kaplan–Meier plots of patients with high circMYLK expression (n = 31) and low circMYLK expression (n = 31). Using median circMYLK values as cutoff. ***P < 0.001, **P < 0.01

Table 2 Correlation between clinical pathological characteristic and MYLK expression in HCC (n = 62)

| Parameters                  | Group         | n   | MYLK expression | P value |
|-----------------------------|---------------|-----|-----------------|---------|
|                             |               |     | High (n = 31)   | Low (n = 31) |
| Age (years)                 | ≤ 60          | 28  | 13              | 15      | 0.515 |
|                             | > 60          | 34  | 18              | 16      |       |
| Gender                      | Female        | 18  | 11              | 7       | 0.302 |
|                             | Male          | 44  | 20              | 24      |       |
| Cirrhosis                   | Positive      | 25  | 15              | 10      | 0.626 |
|                             | Negative      | 37  | 16              | 21      |       |
| AFP (ng/ml)                 | ≤ 400         | 30  | 14              | 16      | 0.728 |
|                             | > 400         | 32  | 17              | 15      |       |
| Tumor size (cm)             | ≥ 5           | 38  | 28              | 10      | 0.003**|
|                             | < 5           | 24  | 3               | 21      |       |
| Intrahepatic metastasis     | Positive      | 21  | 5               | 16      | 0.022*|
|                             | Negative      | 41  | 26              | 15      |       |
| Extrahepatic metastasis     | Positive      | 19  | 2               | 17      | 0.004**|
|                             | Negative      | 43  | 29              | 14      |       |
| BCLC stage                  | A             | 12  | 2               | 10      | 0.065 |
|                             | B             | 34  | 20              | 14      |       |
|                             | C             | 16  | 9               | 7       |       |
| Differentiation             | Well-moderate | 38  | 20              | 18      | 0.173 |
|                             | Moderate to low–low | 24  | 11              | 13      |       |

*P < 0.05, **P < 0.01
These results suggested that inhibition of circMYLK could restrain the ability proliferation and metastasis of HCC cells.

Identification of miR-362-3p as circMYLK target gene
Numerous researches have excavated circRNAs are mainly involved in regulating gene expressions by acting as microRNA (miRNA) sponges [31], according to this point, we speculated that miR-362-3p contained circMYLK possible binding sites through biological information Starbase software (Fig. 3a). Next, luc-circMYLK-WT or luc-circMYLK-MUT was co-transfected with miR-362-3p mimic or its control into Hep3B and Huh7 cells. As shown in Fig. 3b, the luciferase activity in Hep3B and Huh7 cells in miR-362-3p + luc-circMYLK-WT group was observably lower than that in the control group (P < 0.01), while there was no significant change in miR-362-3p + luc-circMYLK-MUT group (P > 0.05). Besides, overexpression of circMYLK markedly inhibited miR-362-3p expression in HCC cells, whereas knockdown of circMYLK showed the opposite effect (Fig. 3c, P < 0.01). Furthermore, compared with the normal tissues, the miR-362-3p expression in HCC tissues was remarkably decreased (Fig. 3d, P < 0.01). Simultaneously, there was a significantly negative correlation between miR-362-3p and circMYLK expression in HCC tissues (Fig. 3e, P < 0.001). These results indicated that miR-362-3p was a direct target gene of circMYLK.

Identification of Rab23 as a target gene of miR-362-3p
Biological information Targetscan software found that Rab23 might contain binding sites of miR-362-3p (Fig. 4a). Besides, luc-Rab23-WT or luc-Rab23-MUT was co-transfected with miR-362-3p mimic or its control to Hep3B and Huh7 cells. The results showed that, compared with the control group, the luciferase activity in Hep3B and Huh7 cells in miR-362-3p + luc-Rab23-WT group was observably decreased (P < 0.01), while there was no marked change in miR-362-3p + luc-Rab23-MUT group (Fig. 4b, P > 0.05). In addition, overexpressed
Fig. 3  Identification of miR-362-3p as circMYLK target gene. **a** Schematic diagram of potential binding sites of miR-362-3p and circMYLK. **b** Measurement of the luciferase activity in Hep3B and Huh7 cells. **c-d** Detection of the miR-362-3p expression in HCC cells (**c**) and tissues (**d**). **e** The correlation analysis of miR-362-3p and circMYLK in HCC tissues. ***P < 0.001, **P < 0.01

Fig. 4  Identification of Rab23 as a target gene of miR-362-3p. **a** Schematic diagram of potential binding sites of Rab23 and miR-362-3p. **b** Measurement of the luciferase activity in Hep3B and Huh7 cells. **c-d** Measurement of the Rab23 mRNA (**c**) and protein (**d**) expressions in Hep3B and Huh7 cells. **e** The correlation analysis of Rab23 mRNA and circMYLK in HCC tissues. **f** The correlation analysis of Rab23 mRNA and miR-362-3p in HCC tissues. **P < 0.01 vs control group, #P < 0.05 vs miR-362-3p mimic group
miR-362-3p remarkably suppressed Rab23 expression in HCC cells, while circMYLK showed the opposite effect (Figs. 4c, d, \( P<0.01, P<0.05 \)). Moreover, there was a remarkable positive correlation between Rab23 mRNA and circMYLK expression in HCC tissues (Fig. 4e, \( P<0.001 \)). In addition, a remarkable negative correlation between Rab23 mRNA and miR-362-3p expression was determined in HCC tissues (Fig. 4f, \( P<0.001 \)). The above results proved that Rab23 was a direct target gene of miR-362-3p, and circMYLK could up-regulate the expression of Rab23 by targeting miR-362-3.

Roles of Rab23 and miR-362-3p in circMYLK-stimulated HCC cell proliferation and metastasis

To investigate how circMYLK performed the its biological function, miR-362-3p mimic, and si-Rab23 were transfected into Hep3B and Huh7 cells to explore the effect on cell proliferation and metastasis. As shown in Fig. 5a, b, overexpression of miR-362-3p or knockdown of Rab23 observably inhibited circMYLK- promoted HCC cell proliferation and colony formation (\( P<0.05 \)). Besides, transwell assays showed that overexpressed miR-362-3p or Rab23 knockdown remarkably suppressed the invasion and migration of HCC cells enhanced by circMYLK (Fig. 5c, \( P<0.05 \)). These results demonstrated that circMYLK might up-regulate Rab23 expression by targeting miR-362-3p, thereby promoting HCC cell proliferation and metastasis.

Roles of circMYLK in HCC tumor growth in vivo

The effect of circMYLK on HCC tumor growth in vivo was studied in a tumor xenograft model in mice. The relative expression of circMYLK in tumor tissues was significantly reduced by the transfection of siRNA targeting circMYLK. The miR-362-3p expression was significantly increased by circMYLK knockdown, which was further
enhanced by miR-362-3p mimics (Fig. 6b). As shown in Figs. 6a, c, d, circMYLK knockdown remarkably suppressed the growth of HCC tumors in mice compared with the control group \( (P < 0.01) \), and the volume and weight of HCC tumors in the si-circMYLK + miR-362-3p agonist group were observably lower than those in the si-circMYLK group \( (P < 0.05) \). Besides, knockdown of circMYLK markedly inhibited Rab23 expression in HCC tumors in vivo, and miR-362-3p agonist further suppressed Rab23 expression (Fig. 6e).

**Discussion**

In-depth study on the molecular mechanism of the occurrence and development of HCC and the exploration of biological markers and drug treatment targets for the early diagnosis of HCC are the current research hotspots [32, 33]. CircRNA MYLK has been shown to promote the progression of various tumor diseases [13]. However, the role of circRNA MYLK in HCC has not been reported yet. In this study, qRT-PCR results found that circMYLK expression was remarkably up-regulated in HCC cell lines and tissues. In addition, the survival rate of patients with high circMYLK expression was remarkably lower than that of patients with low circMYLK expression, and circMYLK overexpression was observably correlated with poor prognosis. Yao et al. found that circZKSCAN1 was lowly expressed in HCC cell lines and tissues, and played an inhibitory role in the progression of HCC, which can be used as an effective marker for HCC treatment [11]. Liang et al. reported that the circβ-catenin was overexpressed in HCC tissues, which could accelerate the development of HCC by activating the Wnt pathway [34]. Therefore, this study preliminarily concluded that circMYLK might participate in and promote the progression of HCC.

At present, studies have confirmed that circRNA can be used as the binding site for miRNA sponge to competitively bind to miRNA, so as to make miRNA lose its own functions and regulate the downstream target genes, thus affecting the biological behavior of tumors [35]. Liang et al. found that circ-ABCB10 could be used as a competitive sponge for miR-1271, thus accelerating the development of breast cancer [36]. In this study, biological information Starbase software found that miR-362-3p contained circMYLK possible binding sites. Meanwhile, luciferase reporter assay demonstrated that up-regulated miR-362-3p expression suppressed luciferase activity of the reporter gene of circMYLK’s 3-UTR-wt sequence in HCC cells. Besides, we found that miR-362-3p was negatively regulated by circMYLK in

---

**Fig. 6** Role of circMYLK in HCC tumor growth in vivo. a. Representative images of HCC subcutaneous tumors in mice of each group. b. Measurement of circMYLK and miR-362-3p expressions in the tumor tissues. c, d. Measurement of HCC tumor volume (c) and weight (d) in mice of each group. e. Determination of Rab23 protein expression in HCC tumors of mice in each group. ***\( P < 0.001 \), **\( P < 0.01 \) vs control group, #\( P < 0.05 \) vs si-circMYLK group.
HCC cells, and miR-362-3p was markedly negatively correlated with circMYLK expression in HCC tissues. These results suggested that miR-362-3p was a direct target of circMYLK in HCC. MiRNA can regulate the transcription and translation of mRNA by binding to the 3’UTR region of the target gene [37, 38]. RAB23 is considered as an oncogene, which is involved in the occurrence and development of various tumor diseases [39, 40]. In this study, biological information Targetscan software predicted the possible binding sites of miR-362-3p in Rab23. The luciferase reporter assay proved that Rab23 had a direct targeted binding site matched with miR-362-3p. Simultaneously, Rab23 was negatively correlated with miR-362-3p expression in HCC cells and tissues, while positively correlated with circMYLK expression. The above results confirmed that Rab23 had a direct targeting binding effect with miR-362-3p, and circMYLK could up-regulate the expression of Rab23 by targeting miR-362-3.

Abnormal proliferation and invasion are important characteristics of tumor cells, and invasion and metastasis of cancer cells will lead to poor prognosis of liver cancer patients after surgery [41]. Therefore, exploring the molecular mechanism of abnormal proliferation, migration and invasion of HCC cells is the key to better understand HCC metastasis and identify potential therapeutic targets. In this study, we found that knockdown of circMYLK observably reduced the cell viability and colony formation ability of Hep3B and Huh7 cells, and remarkably inhibited the invasion and migration ability of HCC cells. Besides, overexpressed miR-362-3p or Rab23 knockdown markedly inhibited circMYLK-enhanced HCC cell proliferation and colony formation, and dramatically suppressed circMYLK-enhanced HCC cell invasion and migration. Interestingly, the level of Rab23 in circMYLK + si-Rab23 group was higher than the control group. That means there might be the additional targets of circMYLK in the process which the circMYLK regulated it in the HCC. Yu et al. showed that circRNA Cdr1as was overexpressed in HCC tissues and cells, and enhanced the invasion and proliferation of HCC cells by regulating the expression of miR-7/PIK3CD/CCNE1 axis [42]. Visually, we described a schematic diagram of circMYLK-regulated miR-362-3p/Rab23 axis (Fig. 7) to address the results of this study suggested that circMYLK might up-regulate Rab23 expression by targeting miR-362-3p, thereby promoting HCC cell proliferation and metastasis. Furthermore, the role of circMYLK in HCC tumor growth in vivo was also studied in a tumor xenograft model in mice. The results found that knockdown of circMYLK remarkably inhibited the growth of HCC tumor and the expression of Rab23 in mice, and miR-362-3p agonist further enhanced this inhibitory effect. It was further confirmed that circMYLK could promote the growth of HCC tumor in vivo by suppressing miR-362-3p and up-regulating Rab23 expression.

**Conclusion**
This study explored the potential molecular mechanism of circMYLK in HCC, and our results demonstrated that circMYLK could alleviate the inhibition of miR-362-3p on Rab23 expression by targeting miR-362-3p, thus promoting the occurrence and development of HCC, which provide a new direction and theoretical basis for the early diagnosis and treatment of liver cancer.
Abbreviations
circRNA MYLK: CircRNA myosin light chain kinase; HCC: hepatocellular carcinoma; qRT-PCR: quantitative Real-Time PCR; circRNA: CircRNA molecule; miRNA: micro RNA; SD: standard deviation; si-circMYLK: siRNA circMYLK.

Acknowledgements
Not applicable.

Authors’ contributions
ZQL and ZYI: study concepts, study design, literature research, experimental studies, manuscript preparation and editing; YSH and QLZ: definition of intellectual content, literature research experimental studies, manuscript preparation and editing; HYW: literature research, experiments work and manuscript writing; JYY: data acquisition, statistical analysis; HL: clinical study and manuscript preparation. All authors read and approved the final manuscript.

Funding
The present study was funded by Plan projects from science and technology department of Henan province (No 17210231001).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Ethical approval (Approval number: 2017-16125) was obtained from the Ethics Committee of the First Affiliated Hospital of Zhengzhou University. All procedures performed in studies involving human participants or animals were in accordance with the ethical standards of the institutional and national research committee. Written informed consent was obtained from all individual patients included in the study.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 31 May 2019   Accepted: 25 July 2019

Published online: 08 August 2019

References
1. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63(5):844–55.
2. Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol. 2014;28(5):753–70.
3. Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):835–3.
4. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2015;62(3):550.
5. Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. APLS guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–80.
6. Galle PR, Forner A, Llovet JM, Mazzaferro V, et al. AASLD practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2015;63(6):550.
7. Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the ALBI grade. J Clin Oncol. 2015;33(5):541.
8. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–80.
9. Salzman J. Circular RNA expression: its potential regulation and function. Trends Genet. 2016;32(3):309–16.
10. Gu S, Yang X, Li X, Wang J, Gao Y, Shang R, et al. Circular RNA: a new star of noncoding RNAs. Cancer Lett. 2015;365(2):141–8.
11. Yao Z, Luo J, Hu K, Lin J, Huang H, Wang Q, et al. ZKSCAN1 gene and its related circular RNA (circZKSCAN1) both inhibit hepatocellular carcinoma cell growth, migration, and invasion but through different signaling pathways. Mol Oncol. 2017;11(4):422–37.
12. Fu L, Yao T, Chen Q, Mo X, Hu Y, Guo J. Screening differential circular RNA expression profiles reveals hsa_circ_0004018 is associated with hepatocellular carcinoma. Oncotarget. 2017;8(35):58405.
13. Zhong Z, Huang M, Lv M, He Y, Duan C, Zhang L, et al. Circular RNA MYLK as a competing endogenous RNA promotes bladder cancer progression through modulating VEGFA/VEGFR2 signaling pathway. Cancer Lett. 2017;393:305–17.
14. Dai Y, Li D, Chen X, Tan X, Gu J, Chen M, et al. Circular miya myosin light chain kinase (mylk) promotes prostate cancer progression through activating miR-29a expression. Med Sci Monit. 2018;24:3462.
15. Luo B, Tang CM, Chen JS. circRNA and gastrointestinal cancer. J Cell Biochem. 2019;120(7):10956–63.
16. Dong D, Sun H, Li Z, Liu S, Dong C, Fu K, et al. An emerging function of circRNA-miRNAs-mRNA axis in human diseases. Oncotarget. 2017;8(42):73271.
17. Iwakawa H-O, Tomari Y. The functions of microRNAs: mRNA decay and translational repression. Trends Cell Biol. 2015;25(11):651–65.
18. Dudekula DB, Panda AC, Grammatikakis I, De S, Abdelmohsen K, Gorospe M. Circleinteractome: a web tool for exploring circular RNAs and their interacting proteins and microRNAs. RNA Biol. 2016;13(1):34–42.
19. Augello C, Colombo F, Terrasi A, Trombetta E, Maggioni M, Porletti R, et al. Expression of C19MC miRNAs in HCC associates with stem-cell features and the cancer-tests genes signature. Dig Liver Dis. 2018;50(6):583–93.
20. Nayak B, Nadda N, Yadav D, Paul SB, Acharya SK. Differential expression of circulating miRNAs among healthy, diseased controls and HCC patients—pilot study. J Clin Exp Hepatol. 2016;6:566–7.
21. Zou X, Zhong J, Li J, Xu Z, Chen Y, Deng W, et al. miR-362-3p targets nemo-like kinase and functions as a tumor suppressor in renal cancer cells. Mol Med Rep. 2016;13(1):994–1002.
22. Shen H, Li W, Tian Y, Xu P, Wang H, Zhang J, et al. Upregulation of miR-362-3p modulates proliferation and anchorage-independent growth by directly targeting Tob2 in hepatocellular carcinoma. J Cell Biochem. 2015;116(8):1563–73.
23. Yu G, Fang P, Chen K, Xu Q, Song Z, Ouyang Z. MicroRNA-362-3p Targets PAX3 to inhibit the development of glioma through mediating Wnt/B-catenin pathway. Neuroimmunomodulation. 2019. https://doi.org/10.1159/000499766.
24. Chen R, Xia W, Wang S, Xu Y, Ma Z, Xu W, et al. Long noncoding RNA SBF2-AS1 is critical for tumorigenesis of early-stage lung adenocarcinoma. Mol Ther Nucleic Acids. 2019;4:543–53.
25. Hor CH, Tang BL, Goh EL. Rab23 and developmental disorders. Rev Neurosci. 2012;23(98):849–60.
26. Zhang W, Yu F, Wang Y, Zhang Y, Meng L, Chi Y. Rab23 promotes the cisplatin resistance of ovarian cancer via the Shh–Gli–ABCG2 signaling pathway. Oncol Lett. 2018;15(4):5155–60.
27. Chen Y, Ng F, Tang BL. Rab23 activities and human cancer—emerging connections and mechanisms. Tumor Biol. 2016;37(10):12959–67.
28. Wang Y, Qin H. miR-338-3p targets Rab23 and suppresses tumorigenicity of prostate cancer cells. Am J Cancer Res. 2018;8(12):2564.
29. Chang J, Xu W, Liu G, Du X, Li X. Downregulation of Rab23 in prostate cancer inhibits tumor growth in vitro and in vivo. Oncol Res Fertil Clin Cancer Ther. 2017;25(2):241–8.
30. Cooper EA, Reddy S, Allenson AZ, Cooper DP, Fowler PA, Rae MT, et al., QRT-PCR analysis of the effect of in utero exposure to sewage sludge on steroidogenic gene expression in ovine foetal adrenal gland. Presented at Society for Endocrinology BES 2018, Glasgow, UK. Endocrine Abstracts. 2018;59: P038. https://www.endocrine-abstracts.org/ea/0059/abstract/10059/p038.
31. Peng L, Chen G, Zhu Z, Shen Z, Du C, Zhang R, et al. Circular RNA ZNFS09 functions as a competitive endogenous RNA to regulate AKT3 expression by sponging miR-150-5p in Hirschsprung’s disease. Oncotarget. 2017;8(1):808.
32. Li L, Zhao GD, Shi Z, Wu X, Li X, Xiao B, et al. miR-320a inhibits hepatocellular carcinoma progression through regulating CDKN2B and the cancer-testis genes signature. Dig Liver Dis. 2018;50(4):835–53.
33. Luo J, Zhou H, Fu L, Liu Z, Li J, Chen K, et al. YTHDC1 promotes the Wnt/β-catenin pathway. Neuroimmunomodulation. 2019. https://doi.org/10.1159/000499766.
34. Li L, Zhao GD, Shi Z, Wu X, Li X, Xiao B, et al. miR-320a inhibits hepatocellular carcinoma progression through regulating CDKN2B and the cancer-testes genes signature. Dig Liver Dis. 2018;50(4):835–53.
35. Luo J, Zhou H, Fu L, Liu Z, Li J, Chen K, et al. YTHDC1 promotes the Wnt/β-catenin pathway. Neuroimmunomodulation. 2019. https://doi.org/10.1159/000499766.
recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol. 2017;67(5):933–9.
34. Liang W-C, Wong C-W, Liang P-P, Shi M, Cao Y, Rao S-T, et al. Translation of the circular RNA circβ-catenin promotes liver cancer cell growth through activation of the Wnt pathway. Genome Biol. 2019;20(1):84.
35. Thomson DW, Dinger ME. Endogenous microRNA sponges: evidence and controversy. Nat Rev Genet. 2016;17(5):272.
36. Liang H-F, Zhang X-Z, Liu B-G, Jia G-T, Li W-L. Circular RNA circ-ABCB10 promotes breast cancer proliferation and progression through sponging miR-1271. Am J Cancer Res. 2017;7(7):1566.
37. Lu L-F, Gasteiger G, Yu I-S, Chaudhry A, Hsin J-P, Lu Y, et al. A single miRNA-mRNA interaction affects the immune response in a context- and cell-type-specific manner. Immunity. 2015;43(1):52–64.
38. Cloonan N. Re-thinking miRNA-mRNA interactions: intertwining issues confound target discovery. BioEssays. 2015;37(4):379–88.
39. Wang M, Dong Q, Wang Y. Rab23 is overexpressed in human astrocytoma and promotes cell migration and invasion through regulation of Rac1. Tumor Biol. 2016;37(8):11049–55.
40. Zhang L, Zhang B, You W, Li P, Kuang Y. Rab23 promotes hepatocellular carcinoma cell migration via Rac1/TGF-β signaling. Pathol Oncol Res. 2018. https://doi.org/10.1007/s12253-018-0463-z.
41. Clark AG, Vignjevic DM. Modes of cancer cell invasion and the role of the microenvironment. Curr Opin Cell Biol. 2015;36:13–22.
42. Yu L, Gong X, Sun L, Zhou Q, Lu B, Zhu L. The circular RNA Cdr1as act as an oncogene in hepatocellular carcinoma through targeting miR-7 expression. PLoS ONE. 2016;11(7):e0158347.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.